Citigroup
MLTX icon

Citigroup’s MoonLake Immunotherapeutics MLTX Stock Holding History

Citigroup’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,000
Closed -$1.17M – 5814
2025
Q1 		$1.17M Buy
30,000
+5,000
+20% +$215K ﹤0.01% 3139
2024
Q4 		$1.35M Buy
+25,000
New +$1.28M ﹤0.01% 3122
2024
Q1 		– Sell
-14,900
Closed -$900K – 5777
2023
Q4 		$900K Buy
+14,900
New +$768K ﹤0.01% 2913

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Citigroup's MLTX Position: Q1 2026 in Review

Citigroup increased its MoonLake Immunotherapeutics (MLTX) stake by 1,405% in Q1 2026, buying an estimated $212K and bringing the position to 13,691 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #3888.

Citigroup first reported a position in MLTX in Q2 2022 and has held it in 13 quarters since. The position peaked at $1.75M in Q4 2022. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Citigroup held 13,691 shares of MoonLake Immunotherapeutics worth $255K as of Q1 2026.
  • Citigroup bought 12,781 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $212K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3888 holding.
  • Citigroup first reported a position in MoonLake Immunotherapeutics in Q2 2022 and has held it in 13 quarters since.
  • Citigroup's MoonLake Immunotherapeutics position peaked at $1.75M in Q4 2022.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.